See more : IGO Limited (IIDDY) Income Statement Analysis – Financial Results
Complete financial analysis of Cogent Biosciences, Inc. (COGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cogent Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Navios Maritime Holdings Inc. (NM) Income Statement Analysis – Financial Results
- Cornish Metals Inc. (SBWFF) Income Statement Analysis – Financial Results
- Allied Copper Corp. (CPRRF) Income Statement Analysis – Financial Results
- Marimaca Copper Corp. (CROJF) Income Statement Analysis – Financial Results
- Allied Architects, Inc. (6081.T) Income Statement Analysis – Financial Results
Cogent Biosciences, Inc. (COGT)
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Cost of Revenue | 3.59M | 5.88M | 147.00K | 25.74K | 43.71K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.59M | -5.88M | -147.00K | 7.85M | 22.46M | 9.73M | 8.36M | 6.36M | 2.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.67% | 99.81% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 170.17M | 121.63M | 55.91M | 72.65M | 43.71M | 38.29M | 29.83M | 21.99M | 6.85M |
| General & Administrative | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Other Expenses | 0.00 | 3.61M | 2.81M | -246.00K | 78.00K | 320.00K | 274.00K | 681.00K | 0.00 |
| Operating Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Cost & Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Interest Income | 13.08M | 3.99M | 467.00K | 144.00K | 267.00K | 1.15M | 386.00K | 265.00K | 0.00 |
| Interest Expense | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.27M | 5.88M | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M | 830.00K | 179.00K |
| EBITDA | -205.86M | -134.36M | -75.40M | -34.57M | -30.89M | -34.68M | -24.98M | -18.24M | -6.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,139.52% | -143.02% | -356.32% | -298.82% | -287.02% | -214.77% |
| Operating Income | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M | -19.07M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,044.33% | -143.02% | -369.89% | -312.82% | -300.08% | -220.76% |
| Total Other Income/Expenses | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K | 946.00K | 0.00 |
| Income Before Tax | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -950.43% | -141.49% | -354.76% | -304.93% | -285.19% | -220.76% |
| Income Tax Expense | 0.00 | -7.60M | -467.00K | -8.36M | -1.56M | 1.47M | -386.00K | -265.00K | 0.00 |
| Net Income | -192.41M | -132.64M | -71.81M | -66.45M | -30.27M | -34.53M | -25.49M | -18.12M | -6.59M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -844.25% | -134.55% | -354.76% | -304.93% | -285.19% | -220.76% |
| EPS | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| EPS Diluted | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -2.45 | -0.89 |
| Weighted Avg Shares Out | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 5.86M | 5.86M |
| Weighted Avg Shares Out (Dil) | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 7.40M | 7.40M |
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr....
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3...
Cogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) on behalf of the company's shareholders. The investigation seeks to determine whether Cogent Biosciences, Inc.'s directors breached their...
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on:
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials
Source: https://incomestatements.info
Category: Stock Reports